Newsroom

Press Releases

See All

01/09/2023

Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2022 Net Product Revenues
01/05/2023

Sarepta and Catalent Expand Strategic Manufacturing Partnership With Commercial Supply Agreement for Duchenne Muscular Dystrophy Gene Therapy Candidate
01/03/2023

Sarepta Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

Stories & Perspectives

Patient Voices

Creating pathways to LGMD genetic diagnosis: Spotlight on LGMD Grant Award recipient
Advocates & Innovators

Ensuring the Safety of Clinical Trial Participants: Meet Eddie Darton, M.D.
Advocates & Innovators

Dragging tomorrow into today: Meet Rachael Potter, Ph.D.
Inside the Science

Understanding external controls and their importance to clinical trials for rare diseases
Inside the Science

Meaningful measure: Understanding the NSAA, an important Duchenne functional-assessment tool
Culture & Community

What’d you do this summer? Our summer interns share lessons learned
Culture & Community

Pride Proud: What belonging feels like and why representation matters
Advocates & Innovators

A Conversation with CFO Ian Estepan, recipient of the 2022 CFO of the Year award from the Boston Business Journal
Inside the Science

Seroprevalence: What patients should know about pre-existing antibodies to gene therapy
Inside the Science

Patient registries: A catalyst for developing new therapies for rare diseases
Inside the Science

Measurements Used in Clinical Trials for Duchenne Muscular Dystrophy – an Overview
Advocates & Innovators

How a collaboration in the lab led to a seat at the table in Sarepta’s Gene Editing Innovation Center
Culture & Community

Giving Thanks for Our Employees’ Incredible Dedication: Six Employees Explain Why Sarepta is a Top Place to Work
Inside the Science

Welcome to GT‐FAQ!
Advocates & Innovators

Expanding Access to Newborn Screening for Those with Rare Diseases
Patient Voices

Patiently Waiting
Advocates & Innovators

From Art to Science: How One Sarepta Scientist Brings the Arts into the Lab
Patient Voices

Advocacy Community Unites to Support Families
Culture & Community

How Sarepta Infused its Corporate Brand with Urgency and Optimism on Behalf of Patients
Inside the Science

What’s in a name? A lot, for the limb-girdle muscular dystrophy community.

Media Library

Sarepta Corporate Logos, Images & Fact Sheets

Press Contact

Tracy Sorrentino
Executive Director, Public Relations
Sarepta Therapeutics, Inc.
[email protected]
617-274-4052